International Trade Bulletin - Volume 1, Issue 1
Client Alert | 2 min read | 03.20.06
Inside this issue:
- CHINA IN THE SPOTLIGHT
- EUROPE IN THE SPOTLIGHT
- DUTY RECOVERY : Many importers and manufacturers pay unnecessary duty on imported merchandise, either directly or as a cost of procured materials
- BILATERAL TRADE: The proposed U.S. – Korea FTA will be the most commercially significant FTA the U.S. has negotiated since NAFTA
- FOREIGN INVESTMENTS: New Indian investment rules allow foreign retailers to set up majority-owned stores in India – a high-growth market eyed by foreign retailers for years
- AIR TRANSPORT: Controversial U.S. DOT proposal to attract investment in the U.S. Airlines draws fire from both sides of the pond rather than hope for Open Skies
- SANCTIONS: The Office of Foreign Assets Control (“OFAC”) of the U.S. Department of the Treasury has issued an interim final rule outlining a new set of enforcement procedures
- NAFTA: NAFTA provisions on “regional value content” (RVC) calculation causes serious problems for related parties
- DUTY SUSPENSION: The Miscellaneous Tariff Bill (MTB) may be more relevant to your business than it sounds - at least if you are an importer of products that American factories do not produce domestically
- INTERNATIONAL IP PROTECTION: Elements of India’s new patent law which took effect in 2005 have prevented Novartis from obtaining a patent for its cancer drug “Gleevec”
Contacts
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today
